The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Losing weight can be difficult for many reasons, including your genetics, hormones, metabolism, lifestyle factors, and mental ...

Revolutionary weight-loss drugs are transforming U.S. health care, prompting patients to seek diagnoses for obesity-related ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

The power of deep breathing for weight loss While seated, count how many times you breathe ... The payoff is more energy and ...

Sleep apnea is a very common health condition affecting millions worldwide. It is a risk factor for several diseases, like ...

Weight-loss drugs are increasingly prescribed in the U.S., not only for obesity treatment but also to facilitate eligibility ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...